{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:04:08Z","timestamp":1769076248299,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is no consensus regarding the secondary cytoreduction surgery (CRS) in recurrent ovarian cancer patients. The present study aims to determine the value of secondary CRS and the eligible subgroup for this procedure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>96 platinum-sensitive recurrent ovarian cancer patients were recruited from Jiangsu Institute of Cancer Research between 1992 and 2011. Follow-up was conducted based on the surveillance protocol of MD Anderson Cancer Center. Cox proportional hazards model and log-rank test were used to assess the associations between the survival durations and covariates. Logistic regression analysis was used to explore optimal secondary CRS related factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Optimal secondary CRS was associated with time to progression (TTP) and overall survival (OS) in patients (p\u2009&lt;\u20090.01 both). Optimal secondary CRS and asymptomatic recurrent were similarly associated with longer OS (median: 79.2<jats:italic>vs.<\/jats:italic>53.9 and 76.1<jats:italic>vs.<\/jats:italic>56.0\u00a0months with p\u2009=\u20090.02 and p\u2009=\u20090.04, respectively) and TTP (median: 13.9<jats:italic>vs.<\/jats:italic>10.5 and 19.3<jats:italic>vs.<\/jats:italic>9.0\u00a0months with p\u2009=\u20090.02 and p\u2009=\u20090.03, respectively) than counterparts. Optimal initial CRS (p\u2009=\u20090.01), asymptomatic recurrent (p\u2009=\u20090.02) and longer progression-free survival duration (p\u2009=\u20090.02) were the independent indicators of optimal secondary CRS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Optimal secondary CRS had survival benefit for platinum-sensitive epithelial ovarian cancer. Asymptomatic recurrent was one of the recruited factors for this procedure.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1756-9966-32-61","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T16:14:28Z","timestamp":1378138468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer"],"prefix":"10.1186","volume":"32","author":[{"given":"Xia","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,2]]},"reference":[{"issue":"1","key":"697_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63 (1): 11-30. 10.3322\/caac.21166.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"697_CR2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1055-9965.243.14.1","volume":"14","author":"L Yang","year":"2005","unstructured":"Yang L, et al: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005, 14 (1): 243-50.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"24","key":"697_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA: Cancer of the ovary. N Engl J Med. 2004, 351 (24): 2519-29. 10.1056\/NEJMra041842.","journal-title":"N Engl J Med"},{"issue":"3","key":"697_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1245\/s10434-006-9273-8","volume":"14","author":"P Benedetti Panici","year":"2007","unstructured":"Benedetti Panici P, et al: Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007, 14 (3): 1136-42. 10.1245\/s10434-006-9273-8.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"697_CR5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jso.21470","volume":"101","author":"JY Park","year":"2010","unstructured":"Park JY, et al: Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J Surg Oncol. 2010, 101 (5): 418-24.","journal-title":"J Surg Oncol"},{"issue":"2","key":"697_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/j.1600-0412.1998.770220.x","volume":"77","author":"F Landoni","year":"1998","unstructured":"Landoni F, et al: Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy. Acta Obstet Gynecol Scand. 1998, 77 (2): 233-7. 10.1080\/j.1600-0412.1998.770220.x.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"697_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/jso.23094","volume":"106","author":"N Boran","year":"2012","unstructured":"Boran N, et al: Secondary cytoreductive surgery outcomes of selected patients with paclitaxel\/platinum sensitive recurrent epithelial ovarian cancer. J Surg Oncol. 2012, 106 (4): 369-75. 10.1002\/jso.23094.","journal-title":"J Surg Oncol"},{"issue":"9","key":"697_CR8","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, et al: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006, 106 (9): 1933-9. 10.1002\/cncr.21845.","journal-title":"Cancer"},{"issue":"1","key":"697_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","volume":"112","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, Puri I, Chi DS: Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009, 112 (1): 265-74. 10.1016\/j.ygyno.2008.08.033.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"697_CR10","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, et al: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006, 13 (12): 1702-10. 10.1245\/s10434-006-9058-0.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"697_CR11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","volume":"16","author":"P Harter","year":"2009","unstructured":"Harter P, et al: Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009, 16 (5): 1324-30. 10.1245\/s10434-009-0357-0.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"697_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1757-2215-6-14","volume":"6","author":"F Wang","year":"2013","unstructured":"Wang F, et al: CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res. 2013, 6 (1): 14-10.1186\/1757-2215-6-14.","journal-title":"J Ovarian Res"},{"issue":"2","key":"697_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","volume":"19","author":"WJ Tian","year":"2012","unstructured":"Tian WJ, et al: A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012, 19 (2): 597-604. 10.1245\/s10434-011-1873-2.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"697_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/1097-0142(197607)38:1<388::AID-CNCR2820380156>3.0.CO;2-A","volume":"38","author":"CG Moertel","year":"1976","unstructured":"Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976, 38 (1): 388-94. 10.1002\/1097-0142(197607)38:1<388::AID-CNCR2820380156>3.0.CO;2-A.","journal-title":"Cancer"},{"issue":"3","key":"697_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92 (3): 205-16. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"697_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45 (2): 228-47. 10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"1","key":"697_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1006\/gyno.1998.5051","volume":"70","author":"Y Shimizu","year":"1998","unstructured":"Shimizu Y, et al: Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features\u2013problems involved in the architectural grading system. Gynecol Oncol. 1998, 70 (1): 2-12. 10.1006\/gyno.1998.5051.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"697_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1006\/gyno.1998.5328","volume":"73","author":"SG Silverberg","year":"1999","unstructured":"Silverberg SG: Toward the development of a universal grading system for ovarian epithelial carcinoma. Gynecol Oncol. 1999, 73 (1): 170-1. 10.1006\/gyno.1998.5328.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"697_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0020-7292(99)00070-3","volume":"65","author":"S Pecorelli","year":"1999","unstructured":"Pecorelli S, et al: FIGO staging of gynecologic cancer. 1994\u20131997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999, 65 (3): 243-9. 10.1016\/S0020-7292(99)00070-3.","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"697_CR20","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/cncr.20106","volume":"100","author":"RY Zang","year":"2004","unstructured":"Zang RY, et al: Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer. 2004, 100 (6): 1152-61. 10.1002\/cncr.20106.","journal-title":"Cancer"},{"issue":"1","key":"697_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L","volume":"75","author":"RY Zang","year":"2000","unstructured":"Zang RY, et al: Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000, 75 (1): 24-30. 10.1002\/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L.","journal-title":"J Surg Oncol"},{"issue":"10","key":"697_CR22","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.ejso.2009.03.010","volume":"35","author":"X Cheng","year":"2009","unstructured":"Cheng X, et al: The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Eur J Surg Oncol. 2009, 35 (10): 1105-8. 10.1016\/j.ejso.2009.03.010.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"697_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2004.11.057","volume":"97","author":"M Gungor","year":"2005","unstructured":"Gungor M, et al: The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005, 97 (1): 74-9. 10.1016\/j.ygyno.2004.11.057.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"697_CR24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/sj.bjc.6602466","volume":"92","author":"T Onda","year":"2005","unstructured":"Onda T, et al: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer. 2005, 92 (6): 1026-32. 10.1038\/sj.bjc.6602466.","journal-title":"Br J Cancer"},{"issue":"3","key":"697_CR25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1006\/gyno.2001.6404","volume":"83","author":"C Scarabelli","year":"2001","unstructured":"Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001, 83 (3): 504-12. 10.1006\/gyno.2001.6404.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"697_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","volume":"88","author":"SM Eisenkop","year":"2000","unstructured":"Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000, 88 (1): 144-53. 10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X.","journal-title":"Cancer"},{"issue":"24","key":"697_CR27","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1056\/NEJMoa041125","volume":"351","author":"PG Rose","year":"2004","unstructured":"Rose PG, et al: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004, 351 (24): 2489-97. 10.1056\/NEJMoa041125.","journal-title":"N Engl J Med"},{"issue":"2","key":"697_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ygyno.2004.09.018","volume":"95","author":"AR Munkarah","year":"2004","unstructured":"Munkarah AR, Coleman RL: Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004, 95 (2): 273-80. 10.1016\/j.ygyno.2004.09.018.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"697_CR29","first-page":"189","volume":"61","author":"JS Berek","year":"1983","unstructured":"Berek JS, et al: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983, 61 (2): 189-93.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"697_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/cncr.22447","volume":"109","author":"R Salani","year":"2007","unstructured":"Salani R, et al: Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007, 109 (4): 685-91. 10.1002\/cncr.22447.","journal-title":"Cancer"},{"issue":"3","key":"697_CR31","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygyno.2007.04.006","volume":"106","author":"SJ Tebes","year":"2007","unstructured":"Tebes SJ, et al: Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007, 106 (3): 482-7. 10.1016\/j.ygyno.2007.04.006.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"697_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1006\/gyno.2001.6143","volume":"81","author":"A Munkarah","year":"2001","unstructured":"Munkarah A, et al: Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol. 2001, 81 (2): 237-41. 10.1006\/gyno.2001.6143.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"697_CR33","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/bjc.2011.328","volume":"105","author":"RY Zang","year":"2011","unstructured":"Zang RY, et al: Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011, 105 (7): 890-6. 10.1038\/bjc.2011.328.","journal-title":"Br J Cancer"},{"issue":"1","key":"697_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0090-8258(89)90593-3","volume":"33","author":"M Morris","year":"1989","unstructured":"Morris M, Gershenson DM, Wharton JT: Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecol Oncol. 1989, 33 (1): 1-5. 10.1016\/0090-8258(89)90593-3.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"697_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3802\/jgo.2009.20.3.198","volume":"20","author":"K Kim","year":"2009","unstructured":"Kim K, Ryu SY: Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009, 20 (3): 198-10.3802\/jgo.2009.20.3.198.","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"697_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3802\/jgo.2009.20.2.101","volume":"20","author":"J Bae","year":"2009","unstructured":"Bae J, et al: Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009, 20 (2): 101-6. 10.3802\/jgo.2009.20.2.101.","journal-title":"J Gynecol Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-32-61.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:05:51Z","timestamp":1715958351000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-32-61"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,2]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-32-61","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,2]]},"assertion":[{"value":"5 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"61"}}